149 related articles for article (PubMed ID: 35458487)
1. Effects of the Prophylactic HPV Vaccines on HPV Type Prevalence and Cervical Pathology.
Hampson IN
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458487
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
[TBL] [Abstract][Full Text] [Related]
3. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
[TBL] [Abstract][Full Text] [Related]
4. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
[No Abstract] [Full Text] [Related]
5. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
[TBL] [Abstract][Full Text] [Related]
6. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
7. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
[TBL] [Abstract][Full Text] [Related]
9. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
10. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
11. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.
Kurosawa M; Sekine M; Yamaguchi M; Kudo R; Hanley SJB; Hara M; Adachi S; Ueda Y; Miyagi E; Ikeda S; Yagi A; Enomoto T
Cancer Sci; 2022 Apr; 113(4):1435-1440. PubMed ID: 35100477
[TBL] [Abstract][Full Text] [Related]
14. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
15. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study.
Mesher D; Panwar K; Thomas SL; Beddows S; Soldan K
BMJ Open; 2016 Feb; 6(2):e009915. PubMed ID: 26868944
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study.
Hiramatsu K; Ueda Y; Yagi A; Morimoto A; Egawa-Takata T; Nakagawa S; Kobayashi E; Kimura T; Kimura T; Minekawa R; Hori Y; Sato K; Morii E; Nakayama T; Tanaka Y; Terai Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Okada H; Nakai H; Matsumura N; Mandai M; Saito J; Horikoshi Y; Takagi T; Enomoto T; Shimura K
Hum Vaccin Immunother; 2022 Dec; 18(1):1951098. PubMed ID: 34802371
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review.
Malagón T; Laurie C; Franco EL
Expert Rev Vaccines; 2018 May; 17(5):395-409. PubMed ID: 29715059
[TBL] [Abstract][Full Text] [Related]
18. The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study.
Naslazi E; Hontelez JAC; Naber SK; van Ballegooijen M; de Kok IMCM
Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):912-919. PubMed ID: 33837119
[TBL] [Abstract][Full Text] [Related]
19. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
[TBL] [Abstract][Full Text] [Related]
20. Indications and efficacy of the human papillomavirus vaccine.
Hakim AA; Lin PS; Wilczynski S; Nguyen K; Lynes B; Wakabayashi MT
Curr Treat Options Oncol; 2007 Dec; 8(6):393-401. PubMed ID: 18172770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]